Clozapine

Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Fitton A, Benfield P. Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia. Pharmacoeconomics. 1993;4(2):131-56. PubMed PMID: 10146973.

Comments on the role of therapeutic drug monitoring for clozapine.

Preskorn SH. Comments on the role of therapeutic drug monitoring for clozapine. J Psychiatr Pract. 2005;11(5):340-3. PubMed PMID: 16184073.

Suicidal risk during treatment with clozapine: a meta-analysis.

Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophrenia Res. 2005;73(2-3):139-45. DOI: 10.1016/j.schres.2004.05.015. PubMed PMID: 15653256.

Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine.

Spivak B, Roitman S, Vered Y, Mester R, Graff E, Talmon Y, et al. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol. 1998;21(4):245-50. PubMed PMID: 9704166.

The InterSePT suicide scale for prediction of imminent suicidal behaviors.

Ayer DW, Jayathilake K, Meltzer HY. The InterSePT suicide scale for prediction of imminent suicidal behaviors. Psychiatry Res. 2008;161(1):87-96. DOI: 10.1016/j.psychres.2007.07.029. PubMed PMID: 18786729.

Clozapine use and outcomes among patients with treatment resistant schizophrenia.

El-Badri S, Mellsop G. Clozapine use and outcomes among patients with treatment resistant schizophrenia. Australas Psychiatry. 2011;19(5):410-4. DOI: 10.3109/10398562.2011.602078. PubMed PMID: 21864010.

Addressing nonresponse in schizophrenia.

Kane JM. Addressing nonresponse in schizophrenia. J Clin Psychiatry. 2012;73(2):e07. DOI: 10.4088/JCP.11076tx2c. PubMed PMID: 22401484.

Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.

Kelly DL, Feldman S, Boggs DL, Gale E, Conley RR. Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia. Compr Psychiatry. 2010;51(3):298-302. DOI: 10.1016/j.comppsych.2009.07.003. PubMed PMID: 20399340.

Early response to clozapine in schizophrenia.

Stern RG, Kahn RS, Davidson M, Nora RM, Davis KL. Early response to clozapine in schizophrenia. Am J Psychiatry. 1994;151(12):1817-8. PubMed PMID: 7977893.

Predictors of differential response to clozapine and haloperidol. Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

Rosenheck R, Lawson W, Crayton J, Cramer J, Xu W, Thomas J, et al. Predictors of differential response to clozapine and haloperidol. Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Biol Psychiatry. 1998;44(6):475-82. PubMed PMID: 9777179.